AlphAIAlphAI — Financial news for AI agents
londoninsider.co.ukSEP 163 min read$BMY

Bristol Myers Squibb And Ono Pharmaceutical Sue Amgen (AMGN) To Block Opdivo Biosimilar

Bristol Myers Squibb (BMY) and Ono Pharmaceutical sued Amgen (AMGN) to block its biosimilar version of Opdivo, alleging patent infringement. Opdivo generated $5.9B in U.S. sales last year. Amgen aims to be among the first Opdivo biosimilars, with FDA approval sought.

Original reporting
londoninsider.co.uk
Published Sep 16, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 10:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bristol Myers Squibb And Ono Pharmaceutical Sue Amgen (AMGN) To Block Opdivo Biosimilar — source image
Source · londoninsider.co.uk
Decision brief

The 30-second read

$BMYBearishMed
01

Why it matters

The case could set precedent for future biosimilar challenges, influencing market expectations for similar drugs.

02

Market read

Legal action may affect stock prices of BMY and AMGN and signal broader competitive pressures in oncology.

03

What to watch

Amgen's pending Keytruda biosimilar and broader pipeline could offset any setback from Opdivo litigation.

Relevance 7/10Novelty 7/10Timing: today

Background

Patent litigation is a common strategy for pharma firms to protect high‑margin biologics.

Company-level read

Ticker impact

$BMYBearishMedium confidence
Context

Bristol Myers Squibb filed a lawsuit to block Amgen's Opdivo biosimilar, protecting its $5.9B revenue stream.

Expected impact

Modest downside risk until case outcome; possible rally if court blocks biosimilar.

Evidence & confidence

Legal action could preserve market share, but uncertainty around court ruling creates volatility.

$AMGNBearishMedium confidence
Context

Amgen seeks FDA approval for an Opdivo biosimilar and is sued by BMY and Ono, risking a sales block.

Expected impact

Potential short‑term dip pending litigation outcome; long‑term upside if biosimilar clears.

Evidence & confidence

Court injunction could halt sales, but Amgen's broader pipeline may mitigate impact.

Market effects

Sector

Could delay biosimilar entry, affecting oncology drug competition and pricing dynamics.

Regional

U.S. biotech and pharma stocks may see heightened volatility.

Global

Highlights ongoing patent battles in the global cancer‑therapy market.

Counterpoint

What could challenge this read

The lawsuit may be a stalling tactic; Amgen could still launch the biosimilar if court denies injunction.

Key entities

  • Company
    Bristol Myers Squibb

    US‑listed pharma with Opdivo revenue of $5.9B.

  • Company
    Amgen

    US‑listed biotech developing Opdivo biosimilar.

  • Company
    Ono Pharmaceutical

    Japanese pharma co‑plaintiff.

Read at source← All news

Related articles

SEP 17
$AMGNLow

Line ITP Market With New Phase 3 Romiplostim Trial

Amgen (AMGN) is conducting a Phase 3 trial comparing romiplostim plus prednisone against prednisone alone for newly diagnosed primary immune thrombocytopenia. The study aims to improve platelet control and reduce steroid exposure. A positive result could expand romiplostim's market and strengthen Amgen's hematology portfolio. The trial is ongoing, with recruitment active.

tipranks.com2 min
SEP 17
$BMYMedAI 9/10

Bristol Myers Squibb reports Sotyktu two-year trial results

Bristol Myers Squibb (BMY) reported two-year Phase 3 trial results for Sotyktu, showing sustained efficacy and no new safety signals in adults with psoriatic arthritis. ACR20/50/70 response rates were 76.2%, 52.6%, and 34.6% at Week 104 for continuous treatment. The company plans to present full results at upcoming medical conferences.

grafa.com2 min
SEP 17
$BMYMedAI 9/10

Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years

Bristol Myers Squibb (BMY) reported two-year data from the POETYK PsA-2 study, showing durable efficacy and consistent safety of Sotyktu (deucravacitinib) in adults with psoriatic arthritis. ACR20/50/70 response rates at Week 104 were 76.2%/52.6%/34.6% (observed) and 65.3%/44.9%/29.4% (NRI) for continuous Sotyktu treatment. Safety profile remained consistent with no new signals. Results were presented at the Congress of Clinical Rheumatology - West.

biospace.com2 min
SEP 17
$BMYMedAI 8/10

BMY Looks 12.4% Overvalued on GF Value™ as Dividend Sustainabili

Bristol-Myers Squibb (BMY) reported positive Phase 3 trial results for Sotyktu in treating psoriatic arthritis. The company offers a 3.95% dividend yield with a 39% payout ratio and a 4.4% 3-year dividend growth rate. BMY's GF Score is 71, indicating strong profitability but modest growth. Insiders and gurus have shown net selling. The stock trades 12.4% above its GF Value of $56.60.

gurufocus.com2 min
SEP 17
$BMYMedAI 8/10

Bristol Myers Squibb reports two-year Sotyktu psoriatic arthritis data

Bristol Myers Squibb (BMY) presented two-year data from the POETYK PsA-2 study, showing continued efficacy and safety of Sotyktu in treating psoriatic arthritis. Key response rates were reported for patients on continuous Sotyktu and those who switched from placebo. The study included 729 patients, with adverse events occurring in 86.6% of participants. Sotyktu was approved earlier this year for this indication.

investing.com2 min